Glycyl-arginin | 851770-00-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glycyl-arginin
• 英文别名: glycyl-arginine；Gly-Arg；2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoic acid
• CAS: 851770-00-8
• 化学式: C₈H₁₇N₅O₃
• 分子量: 231.255
• InChiKey: JLXVRFDTDUGQEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  157
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

  公开号：US20150291659A1

  公开（公告）日：2015-10-15

  Solomanamide analogues of Formula-I having anti-inflammatory activity, and viable synthetic routes for the preparation of such analogues, including the synthesis of macrocyclic core of Salomanamide analogues. The Solomanamide analogues of Formula-I or their pharmaceutical salt may be provided in a pharmaceutical composition and administered in an effective amount for the treatment of inflammation and/or pain.

  公式I的Solomanamide类似物具有抗炎活性，并且具有制备这种类似物的可行合成路线，包括制备Salomanamide类似物的大环核心的合成。公式I的Solomanamide类似物或其药物盐可以在药物组合物中提供，并以有效剂量用于治疗炎症和/或疼痛。
• Detection of Bacteroides gingivalis
  申请人：THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

  公开号：EP0292708A2

  公开（公告）日：1988-11-30

  The present invention relates to the detection of B. gingivalis by the specific ability of B. gingivalis to hydrolyze N-carbobenzoxy-glycyl-glycyl-L-arginine-B-napthylamide deriva­tives. The present invention also relates to the use of assay systems which inhibit serum amino peptidase and enhance the detection of the B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system inhibits the serum enzyme by the use of a serum aminopeptidase inhibitor which inhibits the activity of serum aminopeptidase to a greater extent than it inhibits the activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system also increases the reliability of detection of the B. gingivalis enzyme by the use of enhancing materials which enhance the enzyme activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase to a greater extent than such materials enhance the enzyme activity of serum aminopeptidase.

  本发明涉及通过牙龈杆菌水解 N-羧基苯氧基-甘氨酰-甘氨酰-L-精氨酰-B-萘酰胺衍生物的特异性能力来检测牙龈杆菌。本发明还涉及抑制血清氨基肽酶并提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶检测能力的检测系统的使用。该检测系统通过使用血清氨基肽酶抑制剂来抑制血清酶，该抑制剂对血清氨基肽酶活性的抑制程度大于对牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶活性的抑制程度。该检测系统还通过使用增强材料提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶的酶活性，其增强程度大于此类材料对血清氨肽酶酶活性的增强程度，从而提高检测牙龈杆菌酶的可靠性。
• NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME
  申请人：Seikagaku Corporation

  公开号：EP1323730A1

  公开（公告）日：2003-07-02

  The present invention relates to a polypeptide represented by the formula:         A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7     (I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.

  本发明涉及一种由式表示的多肽： A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7 (I) (其中 A1 代表一个氢原子或一个精氨酸、赖氨酸、鸟氨酸、瓜氨酸、丙氨酸残基等；A2 代表一个芳香族氨基酸。A2 代表芳香族氨基酸残基；A3、A4 和 A6 代表精氨酸、赖氨酸、鸟氨酸、瓜氨酸或丙氨酸残基，A5 代表酪氨酸、苯丙氨酸、丙氨酸、萘丙氨酸或瓜氨酸残基；A7 代表赖氨酸或精氨酸残基，其中的羧基可能被酰胺化；X 代表 D-鸟氨酰-脯氨酸、脯氨酰-D-鸟氨酸、D-赖氨酰-脯氨酸残基等。条件是 A1、A3、A4、A5、A6 和 A7 中的任一个是丙氨酸残基等、或 X 是瓜氨酸等）或其盐。
• 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
  申请人：Biokine Therapeutics LTD.

  公开号：EP2759302A2

  公开（公告）日：2014-07-30

  The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.

  本发明涉及 T-140 类似肽的新型治疗用途以及包含 T-140 类似肽的组合物。具体而言，本发明提供了用于癌症治疗的组合物和方法。
• 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
  申请人：Biokine Therapeutics LTD.

  公开号：EP2942059A1

  公开（公告）日：2015-11-11

  The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.

  本发明涉及 T-140 类似肽的新型治疗用途以及包含 T-140 类似肽的组合物。具体而言，本发明提供了用于癌症治疗的组合物和方法。